|
|
||||||||
From the Department of Clinical Neurosciences (S.J.C., T.T.W.), Royal Free and University College Medical School, London, UK; Neurological Outcomes Measures Unit (S.J.C., J.C.H., A.J.T.), Institute of Neurology, University College London, London, UK; Department of Clinical Neurosciences (J.C.H.,), Peninsula Medical School, Plymouth, UK; Sobell Department of Motor Neuroscience and Movement Disorders (M.E., K.B.), University College London, London, UK; and Department of Public Health (R.F.), University of Oxford, Oxford, UK.
Address correspondence and reprint requests to Dr. Thomas T. Warner, Department of Clinical Neurosciences, Royal Free and University College Medical School, Rowland Hill Street, London, NW3 2PF, UK; e-mail: t.warner{at}medsch.ucl.ac.uk
We compared the responsiveness of the Cervical Dystonia Impact Profile (CDIP-58), Medical Outcome Study Short Form-Health Survey (SF-36), Functional Disability Questionnaire (FDQ), and Pain and Activities of Daily Living subscales of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in participants with cervical dystonia treated with botulinum toxin A. Subscales of CDIP-58 were more sensitive in detecting statistical and clinical change than comparable subscales of the SF-36, FDQ, and TWSTRS.
Supported by a project grant from the Wellcome Trust and additional support from the Dystonia Society (UK) and European Dystonia Federation. Dr. Hobart was supported in part by a grant from the NHS Health Technology Assessment Programme, but the views and opinions expressed do not necessarily reflect those of the executive.
Disclosure: The authors report no conflict of interests.
Received April 14, 2006. Accepted in final form August 30, 2006.
This article has been cited by other articles:
![]() |
B. E Crowner Cervical Dystonia: Disease Profile and Clinical Management Physical Therapy, November 1, 2007; 87(11): 1511 - 1526. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |